Immuneering (NASDAQ:IMRX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Immuneering (NASDAQ:IMRX) posted its quarterly earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01), FiscalAI reports.

Immuneering Stock Up 1.1%

Shares of Immuneering stock traded up $0.05 on Friday, hitting $4.51. The company’s stock had a trading volume of 720,241 shares, compared to its average volume of 1,427,583. The company has a market capitalization of $291.80 million, a P/E ratio of -4.34 and a beta of 0.43. Immuneering has a 52-week low of $2.90 and a 52-week high of $10.08. The firm has a fifty day moving average price of $4.59 and a 200-day moving average price of $4.98.

Hedge Funds Weigh In On Immuneering

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SummitTX Capital L.P. acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $69,000. Price T Rowe Associates Inc. MD raised its position in shares of Immuneering by 10.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after purchasing an additional 195,176 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Immuneering during the 4th quarter worth approximately $607,000. OMERS ADMINISTRATION Corp purchased a new stake in Immuneering in the 4th quarter valued at approximately $315,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Immuneering in the 4th quarter valued at approximately $542,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on IMRX. UBS Group set a $14.00 price objective on shares of Immuneering in a report on Thursday. Needham & Company LLC increased their target price on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a report on Monday, July 20th. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Chardan Capital raised Immuneering to a “strong-buy” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $17.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.